Literature DB >> 18534754

Assessment of forebrain-dependent trace eyeblink conditioning in chronic cannabis users.

Chad R Edwards1, Patrick D Skosnik, Adam B Steinmetz, Jennifer M Vollmer, Brian F O'Donnell, William P Hetrick.   

Abstract

While CB1 knockout mice exhibit striking impairments on a cerebellar-dependent task called delay eyeblink conditioning (dEBC), these animals demonstrate intact forebrain-dependent trace EBC (tEBC). Although heavy human cannabis users also show impaired delay EBC, their performance on tEBC is currently unknown. Therefore, 13 heavy cannabis users and 13 cannabis naive controls completed a tEBC procedure. The cannabis group exhibited similar rates of conditioned responding compared to controls in the acquisition and extinction phase. Consistent with reports of overt attentional abnormalities, the cannabis group exhibited decreased N100 ERP amplitudes to the tone CS that were unrelated to mean levels of conditioning across blocks during the acquisition phase. The lack of a significant effect of heavy cannabis use on tEBC reported here, combined with the previous report of impaired dEBC in such users, mirrors the findings observed in CB1 knockout mice, and suggests that the cannabinoid system differentially mediates forebrain- and cerebellar-dependent learning processes in both humans and animals.

Entities:  

Mesh:

Year:  2008        PMID: 18534754     DOI: 10.1016/j.neulet.2008.04.102

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  The effect of chronic cannabinoids on broadband EEG neural oscillations in humans.

Authors:  Patrick D Skosnik; Deepak C D'Souza; Adam B Steinmetz; Chad R Edwards; Jennifer M Vollmer; William P Hetrick; Brian F O'Donnell
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

2.  Central cannabinoid receptors modulate acquisition of eyeblink conditioning.

Authors:  Adam B Steinmetz; John H Freeman
Journal:  Learn Mem       Date:  2010-10-28       Impact factor: 2.460

3.  Differential effects of the cannabinoid agonist WIN55,212-2 on delay and trace eyeblink conditioning.

Authors:  Adam B Steinmetz; John H Freeman
Journal:  Behav Neurosci       Date:  2013-10       Impact factor: 1.912

4.  Evaluation of bidirectional interstimulus interval (ISI) shift in auditory delay eye-blink conditioning in healthy humans.

Authors:  Adam B Steinmetz; Patrick D Skosnik; Chad R Edwards; Amanda R Bolbecker; Joseph E Steinmetz; William P Hetrick
Journal:  Learn Behav       Date:  2011-12       Impact factor: 1.986

5.  Intracerebellar cannabinoid administration impairs delay but not trace eyeblink conditioning.

Authors:  Adam B Steinmetz; John H Freeman
Journal:  Behav Brain Res       Date:  2019-09-24       Impact factor: 3.332

6.  Examining the effects of former cannabis use on cerebellum-dependent eyeblink conditioning in humans.

Authors:  Adam B Steinmetz; Chad R Edwards; Jennifer M Vollmer; Molly A Erickson; Brian F O'Donnell; William P Hetrick; Patrick D Skosnik
Journal:  Psychopharmacology (Berl)       Date:  2011-12-02       Impact factor: 4.530

7.  Cannabinoid modulation of memory consolidation within the cerebellum.

Authors:  Adam B Steinmetz; John H Freeman
Journal:  Neurobiol Learn Mem       Date:  2016-11-03       Impact factor: 2.877

8.  Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure.

Authors:  Laura Cutando; Arnau Busquets-Garcia; Emma Puighermanal; Maria Gomis-González; José María Delgado-García; Agnès Gruart; Rafael Maldonado; Andrés Ozaita
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

9.  Task-specific enhancement of hippocampus-dependent learning in mice deficient in monoacylglycerol lipase, the major hydrolyzing enzyme of the endocannabinoid 2-arachidonoylglycerol.

Authors:  Yasushi Kishimoto; Barbara Cagniard; Maya Yamazaki; Junko Nakayama; Kenji Sakimura; Yutaka Kirino; Masanobu Kano
Journal:  Front Behav Neurosci       Date:  2015-06-02       Impact factor: 3.558

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.